201 related articles for article (PubMed ID: 32630326)
1. Corporate Characteristics and Adoption of Good Manufacturing Practice for Dietary Supplements in Japan.
Sato K; Kodama K; Sengoku S
Int J Environ Res Public Health; 2020 Jul; 17(13):. PubMed ID: 32630326
[TBL] [Abstract][Full Text] [Related]
2. Creating an Assessment Indicator of Quality Culture Development in the Generic Pharmaceutical Industry in Japan.
Takahashi S; Takarada T; Kitamura R; Shikano M; Sakurai S
PDA J Pharm Sci Technol; 2024 Feb; 78(1):45-69. PubMed ID: 37848202
[TBL] [Abstract][Full Text] [Related]
3. Institutional barriers and enablers to implementing and complying with internationally accepted quality standards in the local pharmaceutical industry of Pakistan: a qualitative study.
Tauqeer F; Myhr K; Gopinathan U
Health Policy Plan; 2019 Jul; 34(6):440-449. PubMed ID: 31302684
[TBL] [Abstract][Full Text] [Related]
4. Cost benefit of investment on quality in pharmaceutical manufacturing: WHO GMP pre- and post-certification of a Nigerian pharmaceutical manufacturer.
Anyakora C; Ekwunife O; Alozie F; Esuga M; Ukwuru J; Onya S; Nwokike J
BMC Health Serv Res; 2017 Sep; 17(1):665. PubMed ID: 28923044
[TBL] [Abstract][Full Text] [Related]
5. [Pharmaceutical product quality control and good manufacturing practices].
Hiyama Y
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2010; (128):1-16. PubMed ID: 21381389
[TBL] [Abstract][Full Text] [Related]
6. [Shortages of Prescription Drugs Due to Compliance and Quality Issues in Japan].
Izutsu KI; Abe Y; Kurita M; Yoshida H
Yakugaku Zasshi; 2023 Feb; 143(2):139-152. PubMed ID: 36418079
[TBL] [Abstract][Full Text] [Related]
7. Optimizing the Relationship between Regulation and Innovation in Dietary Supplements: A Case Study of Food with Function Claims in Japan.
Sato K; Kodama K; Sengoku S
Nutrients; 2023 Jan; 15(2):. PubMed ID: 36678347
[TBL] [Abstract][Full Text] [Related]
8. Highlights of Good Manufacturing Practice in Japan.
Morita K
J Parenter Sci Technol; 1990; 44(1):35-8. PubMed ID: 2313491
[TBL] [Abstract][Full Text] [Related]
9. Dietary supplements quality analysis tools from the United States Pharmacopeia.
Sarma N; Giancaspro G; Venema J
Drug Test Anal; 2016; 8(3-4):418-23. PubMed ID: 26857794
[TBL] [Abstract][Full Text] [Related]
10. Overview of "The Study in Risk-Based Manufacturing Environmental Control for Non-Sterile Drug Products".
Shirokizawa O; Inoue K; Kamikukita T
PDA J Pharm Sci Technol; 2021; 75(6):490-505. PubMed ID: 33990419
[TBL] [Abstract][Full Text] [Related]
11. Aid conditionalities, international Good Manufacturing Practice standards and local production rights: a case study of local production in Nepal.
Brhlikova P; Harper I; Subedi M; Bhattarai S; Rawal N; Pollock AM
Global Health; 2015 Jun; 11():25. PubMed ID: 26072308
[TBL] [Abstract][Full Text] [Related]
12. Influence of manufacturing practices on quality of pharmaceutical products manufactured in Kenya.
Orwa JA; Keter LK; Ouko SP; Kibwage IO; Rukunga GM
East Afr Med J; 2004 Jun; 81(6):287-92. PubMed ID: 16167675
[TBL] [Abstract][Full Text] [Related]
13. Characteristics, risk management and GMP standards of pharmaceutical companies in China.
Chen H; Qin L; Jiang C; Qin M; Sun Y; Luo J
Front Public Health; 2023; 11():1103555. PubMed ID: 36969675
[TBL] [Abstract][Full Text] [Related]
14. Good manufacturing practice: the role of local manufacturers and competent authorities.
Tomić S; Filipović Sučić A; Ilić Martinac A
Arh Hig Rada Toksikol; 2010 Dec; 61(4):425-36. PubMed ID: 21183434
[TBL] [Abstract][Full Text] [Related]
15. Quality of medicines: Deficiencies found by Brazilian Health Regulatory Agency (ANVISA) on good manufacturing practices international inspections.
Geyer ARC; Sousa VD; Silveira D
PLoS One; 2018; 13(8):e0202084. PubMed ID: 30089162
[TBL] [Abstract][Full Text] [Related]
16. Proposed rule: current good manufacturing practice in manufacturing, packing, or holding dietary ingredients and dietary supplements.
Melethil S
Life Sci; 2006 Mar; 78(18):2049-53. PubMed ID: 16516243
[TBL] [Abstract][Full Text] [Related]
17. Quality Culture and Knowledge Management in the Japanese Pharmaceutical Industry-A Cross-Sectional Study and Case Report.
Takahashi S; Takarada T; Ito K; Shikano M; Sakurai S
PDA J Pharm Sci Technol; 2023; 77(5):350-375. PubMed ID: 37321863
[TBL] [Abstract][Full Text] [Related]
18. A QRM Discussion of Microbial Contamination of Non-sterile Drug Products, Using FDA and EMA Warning Letters Recorded between 2008 and 2016.
Santos AMC; Doria MS; Meirinhos-Soares L; Almeida AJ; Menezes JC
PDA J Pharm Sci Technol; 2018; 72(1):62-72. PubMed ID: 29242394
[TBL] [Abstract][Full Text] [Related]
19. Campaign manufacturing of highly active or sensitizing drugs: a comparison between the GMPs of various Regulatory Agencies.
Petrelli F; Scuri S; Grappasonni I; Nguyen CTT; Cocchini A; Magrini E; Caraffa A
Clin Ter; 2020; 170(1):e66-e73. PubMed ID: 31850487
[TBL] [Abstract][Full Text] [Related]
20. The impact of cGMP compliance on consumer confidence in dietary supplement products.
Crowley R; FitzGerald LH
Toxicology; 2006 Apr; 221(1):9-16. PubMed ID: 16469425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
